Zolgensma

News

Boy in wheelchair, only lower half of his body visible

Novartis' SMA gene therapy cleared for wider use in US

A new FDA approval means Novartis now has a gene therapy option for almost everyone with spinal muscular atrophy (SMA), regardless of their age.

News

US/EU regulators start review of Biogen's high-dose Spinraza

Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?

News

New data could widen use of Novartis' SMA therapy Zolgensma

Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.

News

Free access to Zolgensma curbed, says Novartis

Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company.

News

Novartis reports two liver-related deaths with Zolgensma

Concern about the safety of gene therapies has been thrust into the spotlight again with the news that two patients treated with Novartis' spinal muscular atrophy (SMA) treatment Zolgensma

News

Roche puts pressure on SMA rivals with new FDA approval

Roche and PTC Therapeutics' Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger children with the rare disease, extending its use to include infants less than

Novartis' SMA gene therapy cleared for wider use in US

US/EU regulators start review of Biogen's high-dose Spinraza

New data could widen use of Novartis' SMA therapy Zolgensma

Free access to Zolgensma curbed, says Novartis

Novartis reports two liver-related deaths with Zolgensma

Roche puts pressure on SMA rivals with new FDA approval

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Zolgensma

Editor's Picks